GEP20115324B - Tweak binding antibodies - Google Patents

Tweak binding antibodies

Info

Publication number
GEP20115324B
GEP20115324B GEAP200610459A GEAP2006010459A GEP20115324B GE P20115324 B GEP20115324 B GE P20115324B GE AP200610459 A GEAP200610459 A GE AP200610459A GE AP2006010459 A GEAP2006010459 A GE AP2006010459A GE P20115324 B GEP20115324 B GE P20115324B
Authority
GE
Georgia
Prior art keywords
binding antibodies
tweak binding
protein
tweak
tnf
Prior art date
Application number
GEAP200610459A
Other languages
English (en)
Inventor
Linda C Burkly
Ellen A Garber
Alexey Lugovskoy
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of GEP20115324B publication Critical patent/GEP20115324B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
GEAP200610459A 2005-05-27 2006-05-25 Tweak binding antibodies GEP20115324B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68514905P 2005-05-27 2005-05-27

Publications (1)

Publication Number Publication Date
GEP20115324B true GEP20115324B (en) 2011-11-10

Family

ID=37482143

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP200610459A GEP20115324B (en) 2005-05-27 2006-05-25 Tweak binding antibodies

Country Status (29)

Country Link
US (2) US8048422B2 (OSRAM)
EP (3) EP2460832A3 (OSRAM)
JP (4) JP5175181B2 (OSRAM)
KR (2) KR101679468B1 (OSRAM)
CN (3) CN102441163A (OSRAM)
AU (1) AU2006252830B2 (OSRAM)
BR (1) BRPI0611414B8 (OSRAM)
CA (1) CA2609600C (OSRAM)
CY (1) CY1118343T1 (OSRAM)
DK (2) DK2460831T3 (OSRAM)
EA (1) EA018255B1 (OSRAM)
ES (2) ES2605945T3 (OSRAM)
GE (1) GEP20115324B (OSRAM)
HU (1) HUE030701T2 (OSRAM)
IL (1) IL187585A (OSRAM)
IS (1) IS8693A (OSRAM)
LT (1) LT2460831T (OSRAM)
ME (2) ME00261B (OSRAM)
MX (1) MX339015B (OSRAM)
NO (1) NO20076607L (OSRAM)
NZ (2) NZ564092A (OSRAM)
PL (3) PL218791B1 (OSRAM)
PT (2) PT2460831T (OSRAM)
RS (1) RS55888B1 (OSRAM)
SG (1) SG162728A1 (OSRAM)
SI (2) SI2460831T1 (OSRAM)
UA (1) UA96416C2 (OSRAM)
WO (1) WO2006130374A2 (OSRAM)
ZA (1) ZA200710765B (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
EA004590B1 (ru) 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
CN103536916B (zh) * 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
EP1811838A4 (en) * 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
EP1859277A4 (en) 2005-02-17 2010-03-17 Biogen Idec Inc TREATMENT OF NEUROLOGICAL DISORDERS
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP2069521A4 (en) * 2006-10-16 2009-12-16 Biogen Idec Inc BIOMARKERS OF SCLEROSIS IN PLATE
US8685741B1 (en) * 2007-03-07 2014-04-01 Nestec S.A. Methods for diagnosing irritable bowel syndrome
EP2899209A1 (en) 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
MY160126A (en) 2009-05-13 2017-02-28 Genzyme Corp Anti-human cd52 immunoglobulins
RU2012112550A (ru) * 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
US8716450B2 (en) * 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011065940A1 (en) 2009-11-24 2011-06-03 Biogen Idec Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
WO2011097500A2 (en) 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
SG188944A1 (en) * 2010-06-24 2013-05-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201300418A1 (ru) 2010-10-05 2013-09-30 Ф.Хоффманн-Ля Рош Аг Антитела к человеческому tweak и варианты их применения
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
CN104245738B (zh) 2012-04-05 2018-02-02 弗·哈夫曼-拉罗切有限公司 针对人tweak和人il17的双特异性抗体及其用途
UY35110A (es) 2012-11-01 2014-05-30 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
EP3052128A2 (en) 2013-10-04 2016-08-10 Biogen MA Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
TW202010755A (zh) 2018-05-07 2020-03-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
JP7470108B2 (ja) 2018-10-05 2024-04-17 シファメド・ホールディングス・エルエルシー 血管内血液ポンプおよび使用の方法
BR112021008105A2 (pt) 2018-10-29 2021-08-03 Biogen Ma Inc. variantes de fc5 humanizadas e estabilizadas para intensificação de transporte através de barreira hematoencefálica
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
TWI843763B (zh) * 2018-10-31 2024-06-01 日商安斯泰來製藥股份有限公司 抗人類Fn14抗體
CN112778372B (zh) * 2019-11-11 2025-09-23 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用
TW202302648A (zh) * 2021-03-12 2023-01-16 美商健生生物科技公司 Cd79b抗體於自體免疫治療應用之用途

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AT396939B (de) * 1990-05-29 1993-12-27 Alois Dipl Ing Dr Jungbauer Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
TR199900903T2 (xx) 1996-08-07 1999-06-21 Biogen, Inc. Bir t�m�r nekroz fakt�r� ailesine ili�kin protein
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
EP0977887A2 (en) 1997-02-12 2000-02-09 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
ATE424459T1 (de) 1997-10-10 2009-03-15 Genentech Inc Apo-3 ligand
WO2000023459A1 (en) * 1998-10-16 2000-04-27 Immunex Corporation Inhibitors of platelet activation and recruitment
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
EA004590B1 (ru) 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
US7410941B1 (en) * 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
EP2298333A3 (en) 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
JP2004500844A (ja) 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
NZ525140A (en) 2000-09-14 2005-10-28 Biogen Idec Inc Tweak receptor and Fn14 agonists as anti-angiogenic agents
DE60205923T2 (de) 2001-09-27 2006-05-18 Matsushita Electric Industrial Co., Ltd., Kadoma Übertragungsverfahren, sendegerät und empfangsgerät
CN103536916B (zh) 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2005010045A1 (en) 2003-07-24 2005-02-03 Amgen Inc. Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor
EP1566636A1 (en) 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
EP1811838A4 (en) 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
EP1859277A4 (en) 2005-02-17 2010-03-17 Biogen Idec Inc TREATMENT OF NEUROLOGICAL DISORDERS
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
EP1853312B1 (en) 2005-03-07 2014-12-10 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP2069521A4 (en) 2006-10-16 2009-12-16 Biogen Idec Inc BIOMARKERS OF SCLEROSIS IN PLATE

Also Published As

Publication number Publication date
CA2609600A1 (en) 2006-12-07
EA200702643A1 (ru) 2008-04-28
CN103242447B (zh) 2016-04-27
NO20076607L (no) 2008-02-27
BRPI0611414B1 (pt) 2019-04-16
AU2006252830B2 (en) 2012-11-22
CA2609600C (en) 2016-11-08
EA018255B1 (ru) 2013-06-28
WO2006130374A2 (en) 2006-12-07
IL187585A0 (en) 2008-04-13
WO2006130374A3 (en) 2007-12-13
BRPI0611414B8 (pt) 2021-05-25
PL1888113T3 (pl) 2014-11-28
CN103242447A (zh) 2013-08-14
US8048422B2 (en) 2011-11-01
EP1888113B1 (en) 2014-06-25
EP1888113A4 (en) 2009-07-22
IS8693A (is) 2007-11-29
CY1118343T1 (el) 2017-06-28
HUE030701T2 (hu) 2017-05-29
PT1888113E (pt) 2014-09-04
DK1888113T3 (da) 2014-09-01
KR20130140230A (ko) 2013-12-23
NZ564092A (en) 2010-05-28
PL2460831T3 (pl) 2017-05-31
JP6234535B2 (ja) 2017-11-22
JP2008542278A (ja) 2008-11-27
LT2460831T (lt) 2016-12-12
PT2460831T (pt) 2017-01-17
CN101247830A (zh) 2008-08-20
JP2013040210A (ja) 2013-02-28
JP2017025105A (ja) 2017-02-02
HK1169418A1 (en) 2013-01-25
EP2460832A3 (en) 2012-10-31
EP2460831A2 (en) 2012-06-06
MEP35408A (en) 2011-02-10
EP2460831B1 (en) 2016-10-19
ES2507069T3 (es) 2014-10-14
RS55888B1 (sr) 2017-08-31
JP5175181B2 (ja) 2013-04-03
EP1888113A2 (en) 2008-02-20
MX339015B (es) 2016-05-09
AU2006252830A1 (en) 2006-12-07
ZA200710765B (en) 2009-09-30
BRPI0611414A2 (pt) 2010-09-08
CN101247830B (zh) 2013-03-27
SG162728A1 (en) 2010-07-29
KR101679468B1 (ko) 2016-11-24
IL187585A (en) 2012-02-29
US20120009178A1 (en) 2012-01-12
HK1121072A1 (en) 2009-04-17
SI1888113T1 (sl) 2014-10-30
DK2460831T3 (en) 2016-12-19
JP2014221837A (ja) 2014-11-27
SI2460831T1 (sl) 2017-01-31
EP2460831A3 (en) 2012-10-31
UA96416C2 (uk) 2011-11-10
EP2460832A2 (en) 2012-06-06
HK1116423A1 (en) 2008-12-24
ME00261B (me) 2011-02-10
ES2605945T3 (es) 2017-03-17
US20080241163A1 (en) 2008-10-02
KR20080023317A (ko) 2008-03-13
NZ583636A (en) 2011-12-22
PL218791B1 (pl) 2015-01-30
CN102441163A (zh) 2012-05-09
RS20070462A (sr) 2008-11-28

Similar Documents

Publication Publication Date Title
GEP20115324B (en) Tweak binding antibodies
MY149630A (en) Antibodies against amyloid-beta peptide
EA200870274A1 (ru) ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
GEP20125594B (en) Sclerostin binding agents
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
EA201000424A1 (ru) Антитела к il-23
EA201391789A1 (ru) TNF-АЛЬФА АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, ОБЛАДАЮЩИЕ ПОВЫШЕННЫМ СВЯЗЫВАНИЕМ FcRn
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EA201100228A1 (ru) Структурные варианты антител для улучшения терапевтических характеристик
HRP20110334T1 (hr) PROTUTIJELA SPECIFIČNA ZA TGF-ß1
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
NO20071093L (no) Nye anti-IGF-IR-antistoffer og anvendelse derav
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
EA200700136A1 (ru) Анти-cd154-антитела
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
WO2017060322A3 (en) Ptefb-inhibitor-adc
GEP20135826B (en) Novel antibodies used to treat cancer